Reduced Risk of Prostate Cancer With 5α-Reductase Inhibitors.

@article{Thompson2018ReducedRO,
  title={Reduced Risk of Prostate Cancer With 5α-Reductase Inhibitors.},
  author={I. Thompson and P. Goodman and C. Tangen},
  journal={Journal of the National Cancer Institute},
  year={2018},
  volume={110 11},
  pages={
          1159-1160
        }
}
  • I. Thompson, P. Goodman, C. Tangen
  • Published 2018
  • Medicine
  • Journal of the National Cancer Institute
  • Prostate cancer (PCA) and lower urinary tract symptoms (LUTS) associated with aging and benign prostatic hyperplasia are ubiquitous in aging men. PCA has a high prevalence, causes considerable morbidity when metastatic, and is the third most common cause of cancer death in men (1). LUTS adversely affects quality of life and may result in recurrent infections and urinary retention, leading to morbidity and mortality among older men. A seminal clinical trial compared the efficacy of two… CONTINUE READING
    1 Citations
    Response to Walsh.
    • PDF

    References

    SHOWING 1-10 OF 12 REFERENCES
    Risk of Prostate Cancer in Men Treated With 5&agr;-Reductase Inhibitors—A Large Population-Based Prospective Study
    • 12
    • PDF
    The influence of finasteride on the development of prostate cancer.
    • 2,462
    • PDF
    The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
    • 1,608
    • PDF
    Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.
    • 275
    • PDF
    Active surveillance for prostate cancer: current evidence and contemporary state of practice
    • 145
    Finasteride Does Not Increase the Risk of High-Grade Prostate Cancer: A Bias-Adjusted Modeling Approach
    • 186
    • PDF
    Biases in Recommendations for and Acceptance of Prostate Biopsy Significantly Affect Assessment of Prostate Cancer Risk Factors: Results From Two Large Randomized Clinical Trials.
    • 25